학술논문
Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation
Document Type
article
Author
Thiago Moreno L. Souza; Vagner D. Pinho; Cristina F. Setim; Carolina Q. Sacramento; Rodrigo Marcon; Natalia Fintelman-Rodrigues; Otavio A. Chaves; Melina Heller; Jairo R. Temerozo; André C. Ferreira; Mayara Mattos; Patrícia B. Momo; Suelen S. G. Dias; João S. M. Gesto; Filipe Pereira-Dutra; João P. B. Viola; Celso Martins Queiroz-Junior; Lays Cordeiro Guimarães; Ian Meira Chaves; Pedro Pires Goulart Guimarães; Vivian Vasconcelos Costa; Mauro Martins Teixeira; Dumith Chequer Bou-Habib; Patrícia T. Bozza; Anderson R. Aguillón; Jarbas Siqueira-Junior; Sergio Macedo-Junior; Edineia L. Andrade; Guilherme P. Fadanni; Sara E. L. Tolouei; Francine B. Potrich; Adara A. Santos; Naiani F. Marques; João B. Calixto; Jaime A. Rabi
Source
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Subject
Language
English
ISSN
2041-1723
Abstract
The search for antivirals against SARS-CoV-2 continue due to the emergence of variants of concerns, able to escape the vaccinal humoral response. In this work, authors pre-clinically explore the potential of kinetin against SARS-CoV-2, which could be used alone or in combination with other antivirals.